181 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author배상철-
dc.date.accessioned2017-09-11T06:35:02Z-
dc.date.available2017-09-11T06:35:02Z-
dc.date.issued2015-11-
dc.identifier.citationRHEUMATOLOGY INTERNATIONAL, v. 35, NO 11, Page. 1809-1815en_US
dc.identifier.issn0172-8172-
dc.identifier.issn1437-160X-
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs00296-015-3344-8-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/29037-
dc.description.abstractWe aimed to estimate the annual direct medical costs of South Korean systemic lupus erythematosus (SLE) patients, and their predictors. The 2010 annual direct medical costs of SLE patients in the Hanyang BAE Lupus cohort in South Korea were assessed. The information was taken directly from the hospital database and medical records, and included clinical characteristics, disease activity, organ damage, and healthcare utilization. Cost predictors were estimated with a multivariate linear regression model. A total of 749 SLE patients (92.7 % female, mean age 35.7 +/- A 11.3 years, mean disease duration 9.6 +/- A 4.9 years) were studied. Their mean annual direct medical costs amounted to USD 3305. The largest component of these costs was the cost of medication (USD 1269, 38.4 %), followed by those of diagnostic procedures and tests (USD 1177, 35.6 %). Regression analysis showed that adjusted mean SLE disease activity index score (p ˂ 0.0001), systemic damage index (p ˂ 0.0001), and renal (p = 0.0039) and hematologic (p = 0.0353) involvement were associated with increased direct medical costs, whereas longer disease duration was associated with lower direct medical costs. Greater disease activity and greater organ damage predict higher costs for South Korean SLE patients. Major organ involvement such as renal disorder and hematologic involvement also predicts higher costs, whereas longer duration of disease predicts lower costs.en_US
dc.description.sponsorshipThis study was supported by a grant from GlaxoSmithKline, Korea and the Korea Healthcare Technology R&D project, Ministry for Health & Welfare, Republic of Korea (A120404).en_US
dc.language.isoenen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.subjectCost of illnessen_US
dc.subjectDirect costsen_US
dc.subjectOrgan damageen_US
dc.subjectDisease activityen_US
dc.subjectSystemic lupus erythematosusen_US
dc.titleDirect medical costs and their predictors in South Korean patients with systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.relation.no11-
dc.relation.volume35-
dc.identifier.doi10.1007/s00296-015-3344-8-
dc.relation.page1809-1815-
dc.relation.journalRHEUMATOLOGY INTERNATIONAL-
dc.contributor.googleauthorPark, So-Yeon-
dc.contributor.googleauthorJoo, Young Bin-
dc.contributor.googleauthorShim, Jeeseon-
dc.contributor.googleauthorSung, Yoon-Kyoung-
dc.contributor.googleauthorBae, Sang-Cheol-
dc.relation.code2015003449-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidscbae-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE